Parametric Portfolio Associates’s Marker Therapeutics MRKR Stock Holding History

Parametric Portfolio Associates’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2,554	Closed	-$24K	–	3732
2021 Q4	$24K	Sell	2,554 -1,893	-43%	-$25.1K	﹤0.01%	3620
2021 Q3	$75K	Sell	4,447 -3,060	-41%	-$62.7K	﹤0.01%	3555
2021 Q2	$209K	Sell	7,507 -1,561	-17%	-$41.1K	﹤0.01%	3395
2021 Q1	$203K	Buy	9,068 +1,986	+28%	+$45.4K	﹤0.01%	3874
2020 Q4	$103K	Sell	7,082 -11,536	-62%	-$179K	﹤0.01%	3884
2020 Q3	$279K	Buy	18,618 +10,775	+137%	+$197K	﹤0.01%	3517
2020 Q2	$162K	Buy	7,843 +6,648	+556%	+$145K	﹤0.01%	3680
2020 Q1	$23K	Buy	+1,195	New	+$30.4K	﹤0.01%	3889
2019 Q4	–	Sell	-3,213	Closed	-$164K	–	3987
2019 Q3	$164K	Buy	+3,213	New	+$190K	﹤0.01%	3751

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ACM

ACT Capital Management Wayne, Pennsylvania $153M AUM

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

AAM

AR Asset Management West Hollywood, California $546M AUM 24.08% 1-Year Est. Return

Parametric Portfolio Associates's MRKR Position: Q1 2022 in Review

Parametric Portfolio Associates sold out of Marker Therapeutics (MRKR) in Q1 2022, closing a stake of 2,554 shares — an estimated $24K sold.

Parametric Portfolio Associates first reported a position in MRKR in Q3 2019 and held it in 9 quarters. The position peaked at $279K in Q3 2020. 49 funds tracked by Wall St. Rank hold MRKR as of Q1 2022.

Parametric Portfolio Associates reported no remaining Marker Therapeutics position as of Q1 2022 after selling out during the quarter.
Parametric Portfolio Associates sold 2,554 Marker Therapeutics shares in Q1 2022, an estimated $24K.
Parametric Portfolio Associates first reported a position in Marker Therapeutics in Q3 2019 and held it in 9 quarters.
Parametric Portfolio Associates's Marker Therapeutics position peaked at $279K in Q3 2020.
49 funds tracked by Wall St. Rank held Marker Therapeutics as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.